The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Arcutis Biothereapeutics Common Stock 03969K108 25,543 844,680 SH   SOLE   844,680 0 0
Beam Therapeutics Common Stock 07373V105 8,479 302,821 SH   SOLE   302,821 0 0
Cidara Therapeutics Common Stock 171757107 7,399 2,005,249 SH   SOLE   2,005,249 0 0
ESSA Pharma Common Stock 29668H708 9,284 1,497,448 SH   SOLE   1,497,448 0 0
FibroGen Common Stock 31572Q808 5,295 130,646 SH   SOLE   130,646 0 0
Gossamer Bio Common Stock 38341P102 43,168 3,320,608 SH   SOLE   3,320,608 0 0
Immunic Common Stock 4525EP101 16,623 1,371,494 SH   SOLE   1,371,494 0 0
Jounce Therapeutics Common Stock 481116101 3,657 529,965 SH   SOLE   529,965 0 0
Morphic Holding Common Stock 61775R105 80,489 2,975,582 SH   SOLE   2,975,582 0 0
ObsEva Common Stock H5861P103 5,886 999,364 SH   SOLE   999,364 0 0
Paratek Pharmaceuticals Common Stock 699374302 13,586 2,602,739 SH   SOLE   2,602,739 0 0
Pieris Pharmaceuticals Common Stock 720795103 2,327 750,741 SH   SOLE   750,741 0 0
Prevail Therapeutics Common Stock 74140Y101 2,794 187,538 SH   SOLE   187,538 0 0
Replimune Group Common Stock 76029N106 132,161 5,344,971 SH   SOLE   5,344,971 0 0
Trevi Therapeutics Common Stock 89532M101 9,053 1,375,907 SH   SOLE   1,375,907 0 0